FDA Wants Compounding Authority Clarified, Congress Not So Sure It’s Necessary

Commissioner Hamburg asks for more power over non-traditional compounding to better regulate companies like the New England Compounding Center, but several House members say it looks like the agency already has the authority it needs.

FDA is arguing for more authority over some types of compounding to prevent future problems like the deadly meningitis outbreak at the New England Compounding Center, but many House members are not convinced it is necessary.

Several Republican members of the House Energy and Commerce Committee Oversight and Investigations Committee suggested during a Nov. 14 hearing that the authority already exists and the agency could have...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America

STARGLO Dulled: Genentech’s Columvi Data Not Generalizable To US Patients, FDA Panel Says

 
• By 

The glofitamab trial results are not generalizable due to the small number of enrolled US lymphoma patients and adverse results across multiple endpoints for patients from non-Asian regions, the Oncologic Drugs Advisory Committee said.

Legal, Process Problems May Plague New US FDA COVID-19 Vaccine Policy

 

The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.

Observational, Retrospective Trials Could Retest Vaccines, HHS’ Kennedy Says

 

The Health and Human Services secretary told a Senate appropriations subcommittee that placebo-controlled trials may not be necessary to ensure vaccine safety as the FDA released a framework requiring them for COVID-19 vaccines.